RAPT Therapeutics's IPO Review

TL;DR

Rapid Therapeutics, a subsidiary of Bristol-Myers Squibb, is a San Francisco-based biopharma company focusing on developing small molecule oral therapies for oncology and inflammatory diseases. With a market cap close to $1 billion, it has seen a 269% increase since its IPO in November 2019.

Transcript

hi I'm Angela and welcome to IP go the show where we take a look at the IPO world past present and future today we're looking at a firm that IP owed in November 2000 and 19 and is up an impressive 269 percent already wrapped therapeutics is a SAN francisco-based biopharma company founded in 2015 that operates as a subsidiary of bristol-myers Squibb... Read More

Key Insights

• 🪸 Rapid Therapeutics, a subsidiary of Bristol-Myers Squibb, is a biopharma company focusing on discovering and developing small molecule oral therapies for oncology and inflammatory diseases.
• 💗 The company's market cap has grown significantly since its IPO in November 2019, experiencing a 269% increase.
• ♋ Rapid Therapeutics has two main drugs in its pipeline, F LX 475 for cancer treatment and PT 193 for allergic inflammatory disorders.
• 🍻 Investor excitement is linked to the company's progress in its drug development pipeline, especially collaborations with other pharmaceutical companies.
• 🈷️ The company's cash runway as of September 2019 was around 14 months, which investors will monitor closely.
• ↩️ Rapid Therapeutics may return to the market for additional funding if there are delays in product development.
• 🖕 The next earnings report is expected in mid-March, which could further impact the company's future prospects.

Questions & Answers

Q: What is Rapid Therapeutics focused on?

Rapid Therapeutics is focused on developing small molecule oral therapies for patients with unmet needs in oncology and inflammatory diseases.

Q: What are the two main drugs in Rapid Therapeutics' pipeline?

The two main drugs in Rapid Therapeutics' pipeline are F LX 475, a drug for cancerous tumors, and PT 193, a drug for allergic inflammatory disorders like eczema and asthma.

Q: How has Rapid Therapeutics' market cap changed since its IPO?

Since its IPO in November 2019, Rapid Therapeutics' market cap has increased by an impressive 269%, reaching almost $1 billion.

Q: How is investor excitement linked to Rapid Therapeutics?

Investor excitement in Rapid Therapeutics is mainly due to the progress the company is making in its drug development pipeline, particularly with drugs like F LX 475 and PT 193.

Summary & Key Takeaways

• Rapid Therapeutics, founded in 2015, is a biopharma company focused on discovering, developing, and commercializing small molecule oral therapies for oncology and inflammatory diseases.

• The company has two main drugs in its pipeline: F LX 475 for cancer treatment and PT 193 for allergic inflammatory disorders like eczema and asthma.

• With a market cap of nearly $1 billion, Rapid Therapeutics had a successful IPO, raising $75 million and experiencing substantial growth.